For sponsors developing high-value biologics, every batch matters. As biologics become more complex and regulatory expectations continue to rise, drug product manufacturers face increasing pressure to deliver sterile products quickly while minimizing contamination, compliance, and supply risks. In this technical note, our experts Angela Armanni and Iris Henn explore how next-generation aseptic manufacturing technologies, automation, and innovative facility design can help sponsors move from clinical development to commercial supply with greater confidence.
What you'll learn:
- How evolving Annex I requirements are reshaping aseptic drug product manufacturing strategies.
- Why single-use systems and advanced isolator technology are becoming essential for flexibility, sterility assurance, and rapid changeovers.
- How smart automation can help reduce contamination risks, minimize product loss, and improve manufacturing reliability.
- Approaches to managing extractables and leachables risks while preparing for regulatory submissions.
- How combining advanced technologies with experienced teams can support successful technology transfer, scale-up, and commercial supply.
